AC Immune
Anna Gaglianese is a Senior Data Scientist with experience in neuroscience research and data analysis. Anna has worked in various research institutions and hospitals, specializing in functional organization of the multisensory motion system, prediction of length of stay in intensive care units, and decoding spatial and temporal features of moving visual stimuli. Anna holds a PhD in Neuroscience from Università di Pisa and a Master of Science in Bioengineering and Biomedical Engineering.
AC Immune
3 followers
AC Immune SA is clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen™ and Morphomer™, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features nine therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments.